Rani Therapeutics, a San Jose CA-based developer of a platform to convert injectable drugs into pills, closed its Series B funding of undisclosed amount.
The round was led by Google Ventures, with participation from InCube Ventures and VentureHealth.
The company intends to use the funds for further development of its novel approach for the oral delivery of large drug molecules including peptides, proteins, antibodies, RNAi therapies and select vaccines.
Led by Mir Imran, Chairman & CEO, Rani Therapeutics has developed a novel approach for the oral delivery of large drug molecules, which to date can only be delivered through injections including TNF-alpha Inhibitors (e.g. adalimumab and etanercept) and basal insulin.
FinSMEs
28/08/2013